A Study of Belzutifan Versus Everolimus in Participants With Advanced Renal Cell Carcinoma
The primary objective of this study is to compare belzutifan to everolimus with respect to progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed